{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:39:41Z","timestamp":1787960381059,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.tmrv.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:48:50Z","timestamp":1595504930000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Ioannis","family":"Bellos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximos","family":"Frountzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Pergialiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2020.07.002_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/joim.13004","article-title":"Iron deficiency anaemia revisited","volume":"287","author":"Cappellini","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0010","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0015","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/00365520902839667","article-title":"Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study","volume":"44","author":"Lindgren","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","article-title":"Single-dose intravenous iron for iron deficiency: a new paradigm","volume":"2016","author":"Auerbach","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2017.02.004","article-title":"New insights into iron deficiency and iron deficiency anemia","volume":"31","author":"Camaschella","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jgh3.12150","article-title":"Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose","volume":"3","author":"Fang","year":"2019","journal-title":"JGH Open"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","author":"Klein","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2369-14-167","article-title":"Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study","volume":"14","author":"Prats","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous Iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0075","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0080","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","article-title":"Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources","volume":"331","author":"Greenhalgh","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0085","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. https:\/\/doi.org\/10.1136\/BMJ.D5928.","DOI":"10.1136\/bmj.d5928"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0090","author":"Plummer"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i05","article-title":"Performing arm-based network meta-analysis in R with the pcnetmeta package","volume":"80","author":"Lin","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jrsm.1188","article-title":"The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis","volume":"7","author":"Jackson","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0125","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.1093\/ecco-jcc\/jjx180.735","article-title":"P608 IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with inflammatory bowel disease unable to take oral iron: a randomised controlled trial vs. ferric carboxymaltose","volume":"12","author":"Strauss","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/trf.12289","article-title":"A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia","volume":"54","author":"Onken","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0135","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12884-019-2200-3","article-title":"Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy\u2014randomised controlled trial","volume":"19","author":"Jose","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/172104","article-title":"Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of Iron deficiency anemia: two randomized controlled trials","volume":"2012","author":"Barish","year":"2012","journal-title":"Anemia"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0155","unstructured":"Hypophosphatemia with ferric carboxymaltose vs. iron dextran in iron deficiency secondary to heavy uterine bleeding. ClinicaltrialsGov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01307007?view=results."},{"key":"10.1016\/j.tmrv.2020.07.002_bb0160","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2018-99-114386","article-title":"Hypophosphatemia after high dosage Iron substitution with ferric carboxymaltose (FCM) and Iron isomaltoside (IM)\u2014the randomised controlled Home Afers 1 trial","volume":"132","author":"Emrich","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0165","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0180","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","author":"Bhandari","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0185","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0190","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ejcn.2016.217","article-title":"Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients","volume":"71","author":"Tan","year":"2017","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0205","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/1744-9987.13435","article-title":"Iron infusion and induced hypophosphatemia: the role of fibroblast growth factor-23","volume":"24","author":"Coppolino","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.tmrv.2020.07.002_bb0210","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796320300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796320300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:49Z","timestamp":1760138329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796320300353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0887796320300353"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2020.07.002","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}